SAFETY DATA SHEET



1. Identification

| Product identifier | Furosemide Oral Solution USP |
|-------------------------------|---|
| Other means of identification | None. |
| Recommended use | Treatment of edema associated with congestive heart failure, cirrhosis of the liver, an renal disease |
| Recommended restrictions | None known. |

Manufacturer/Importer/Supplier/Distributor information

| Company name Address | West-Ward Pharmaceuticals Corporation 1809 Wilson Road |
|-------------------------|--|
| | Columbus, Ohio 43228 |
| Telephone | (614) 276-4000 |
| Emergency phone number | (614) 276-4000 |

2. Hazard(s) identification

| Physical hazards | Not classified. |
|--|---|
| Health hazards | Not classified. |
| OSHA defined hazards | Not classified. |
| Label elements | |
| Hazard symbol | None. |
| Signal word | Warning |
| Hazard statement | This is a pharmaceutical product designed to be prescribed by a licensed health care professional. Should any person while using this product observe any adverse health effects, they should seek medical treatment. |
| Precautionary statement | |
| Prevention | Observe good industrial hygiene practices. |
| Response | Wash hands after handling. |
| Storage | Store away from incompatible materials. Store at 25°C (77°F); excursions permitted to 15 - 30 °C (59 - 86 °F). Protect from light. Protect from moisture. |
| Disposal | Incineration of waste at an approved USEPA incinerator is recommended. |
| Hazard(s) not otherwise classified (HNOC) | None known. |

3. Composition/information on ingredients

Substances

The manufacturer lists no ingredients as hazardous according to OSHA 29 CFR 1910.1200.

| Chemical name | Common name and synonyms | CAS number | % |
|---|--|-------------------------------|-----------------------|
| 4-chloro-N-furfuryl-5-sulfamo anthranilic acid | yl | 54-31-9 | 10 - 40 mg/mL |
| Composition comments | Refer to Physician's Desk Reference for comr | non components present | at <1% |
| 4. First-aid measures | | | |
| Inhalation | Move to fresh air. Call a physician if symptom | s develop or persist. | |
| Skin contact | Wash off with soap and water. Get medical at | tention if irritation develop | s and persists. |
| Eye contact | Rinse with water. Get medical attention if irrita | ation develops and persists | 3. |
| Ingestion | Rinse mouth. Get medical attention if symptor call a poison control center immediately. | ns occur. If ingestion of a | large amount does occ |

| Most important symptoms/effects, acute and delayed | Most common side effects are: pancreatitis, jaundice, anorexia, oral and gastric irritation, cramping, diarrhea, constipation, nausea and vomiting |
|--|---|
| Indication of immediate medical attention and special treatment needed | Treatment of over dosage is supportive and consists of replacement of excessive fluids and electrolyte losses. Serum electrolytes, carbon dioxide level and blood pressure should be determined frequently. |
| General information | Ensure that medical personnel are aware of the material(s) involved, and take precautions to protect themselves. |
| E Fire fighting measures | |

5. Fire-fighting measures

| Suitable extinguishing media | Water fog. Foam. Dry chemical powder. Carbon dioxide (CO2). |
|--|---|
| Unsuitable extinguishing media | Do not use water jet as an extinguisher, as this will spread the fire. |
| Specific hazards arising from the chemical | During fire, gases hazardous to health may be formed. |
| Special protective equipment and precautions for firefighters | Self-contained breathing apparatus and full protective clothing must be worn in case of fire. |
| Fire fighting equipment/instructions | Use water spray to cool unopened containers. |
| Specific methods | Use standard firefighting procedures and consider the hazards of other involved materials. |
| General fire hazards | No unusual fire or explosion hazards noted. |

6. Accidental release measures

| Personal precautions, protective equipment and emergency procedures | Keep unnecessary personnel away. Wear appropriate personal protective equipment (See Section 8). |
|---|--|
| Methods and materials for containment and cleaning up | Wipe up with absorbent material. Following product recovery, flush area with water. Incineration of waste at an approved USEPA incinerator is recommended. |
| Environmental precautions | Avoid discharge into drains, water courses or onto the ground. |

7. Handling and storage

Precautions for safe handlingAvoid contact with eyes, skin, and clothing. Wash hands thoroughly after handling.Conditions for safe storage,
including any incompatibilitiesStore away from incompatible materials (see Section 10 of the SDS). Dispense in a tight,
light-resistant container as defined in the USP/NF. Protect from light. Store at 25°C (77°F);
excursions permitted to 15 - 30 °C (59 - 86 °F). Discard opened bottle after 90 days.

8. Exposure controls/personal protection

| Occupational exposure limits | No exposure limits noted for ingredient(s). |
|----------------------------------|--|
| Biological limit values | No biological exposure limits noted for the ingredient(s). |
| Appropriate engineering controls | Ventilation should be matched to conditions. |
| | |

Individual protection measures, such as personal protective equipment

Eye/face protectionNone required for consumer use. In laboratory, medical or industrial settings, safety glasses with
side shields are recommended. The use of goggles or full face protection may be required
depending on the industrial exposure setting. Contact a health and safety professional for specific
information.Skin protection
Hand protection
OtherFor consumer use, no unusual precautions are necessary.None required for consumer use. In laboratory, medical or industrial settings, gloves and lab coats

are recommended. The use of additional personal protective equipment such as shoe coverings, gauntlets, hood or head coverings may be necessary. Contact a health and safety professional for specific information.

| Respiratory protection | None required for consumer use. Respirators may be required for certain laboratory and manufacturing tasks if engineering controls do not maintain airborne concentrations below recommended exposure limits (where applicable) or to an acceptable level (where exposure limits have not been established). Workplace risk assessments should be completed before specifying and implementing respirator usage. All respirators must conform to specifications for efficiency and performance. In the United States of America, if respirators are used, a program should be instituted to assure compliance with OSHA Standard 29 CFR 1910.134. Respirator type: Air-purifying respirator with an appropriate, air-purifying filter, cartridge or canister. Contact a health and safety professional or manufacturer for specific information. |
|-----------------------------------|--|
| Thermal hazards | Wear appropriate thermal protective clothing, when necessary. |
| General hygiene considerations | Always observe good personal hygiene measures, such as washing after handling the material and before eating, drinking, and/or smoking. Routinely wash work clothing and protective equipment to remove contaminants. |

9. Physical and chemical properties

| Appearance | Clear orange liquid. |
|--|---|
| Physical state | Liquid. |
| Form | Liquid. |
| Color | Clear orange. |
| Odor | Not available. |
| Odor threshold | Not available. |
| рH | Not available. |
| Melting point/freezing point | Not available. |
| Initial boiling point and boiling range | Not available. |
| Flash point | Not available. |
| Evaporation rate | Not available. |
| Flammability (solid, gas) | Not available. |
| Upper/lower flammability or expl | losive limits |
| Flammability limit - lower (%) | Not available. |
| Flammability limit - upper (%) | Not available. |
| Explosive limit - lower (%) | Not available. |
| Explosive limit - upper (%) | Not available. |
| Vapor pressure | Not available. |
| Vapor density | Not available. |
| Relative density | Not available. |
| Relative density temperature | estimated |
| Solubility(ies) | |
| Solubility (water) | Insoluble |
| Partition coefficient (n-octanol/water) | Not available. |
| Auto-ignition temperature | Not available. |
| Decomposition temperature | Not available. |
| Viscosity | Not available. |
| 10. Stability and reactivity | |
| Reactivity | The product is stable and non-reactive under normal conditions of use storage and transport |

| Reactivity | The product is stable and non-reactive under normal conditions of use, storage and transport. |
|------------------------------------|---|
| Chemical stability | Material is stable under normal conditions. |
| Possibility of hazardous reactions | No dangerous reaction known under conditions of normal use. |
| Conditions to avoid | Contact with incompatible materials. Exposure to light. |
| Incompatible materials | Strong oxidizing agents. |

11. Toxicological information

| Information on likely routes of e | xposure |
|--|--|
| Inhalation | Not expected to be hazardous in final pharmaceutical form. |
| Skin contact | Not expected to be hazardous in final pharmaceutical form. |
| Eye contact | Not expected to be hazardous in final pharmaceutical form. Direct contact with eyes may cause temporary irritation. |
| Ingestion | Ingestion may cause irritation and malaise. |
| Symptoms related to the physical, chemical and toxicological characteristics | Most common side effects are: pancreatitis, jaundice, anorexia, oral and gastric irritation, cramping, diarrhea, constipation, nausea and vomiting |
| Information on toxicological effe | ects |
| Acute toxicity | May be harmful if swallowed in large quantities. Product is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. |
| Skin corrosion/irritation | Prolonged skin contact may cause temporary irritation. |
| Serious eye damage/eye irritation | Direct contact with eyes may cause temporary irritation. |
| Respiratory or skin sensitizatior | |
| Respiratory sensitization | Not a respiratory sensitizer. |
| Skin sensitization | This product is not expected to cause skin sensitization. |
| Germ cell mutagenicity | The product contains a substance which has demonstrated animal effects of mutagenicity. |
| Carcinogenicity | This product is not considered to be a carcinogen by NTP, IARC, or OSHA. |
| ••• | Evaluation of Carcinogenicity |
| 4-chloro-N-turturyl-5-sulta 54-31-9) | moylanthranilic acid (CAS 3 Not classifiable as to carcinogenicity to humans. |
| , | d Substances (29 CFR 1910.1001-1050) |
| Not listed. | |
| Not noted. | |
| Reproductive toxicity | Because there are no adequate and well-controlled studies in pregnant women, this drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. |
| | |
| | be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. |
| | be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Pregnancy Category C: There are no adequate and well-controlled studies in pregnant women. |
| Reproductive toxicity Specific target organ toxicity - | be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.Pregnancy Category C: There are no adequate and well-controlled studies in pregnant women.This product passes into breast milk. Breast-feeding is not advised in mothers being treated. |
| Reproductive toxicity Specific target organ toxicity - single exposure Specific target organ toxicity - | be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Pregnancy Category C: There are no adequate and well-controlled studies in pregnant women. This product passes into breast milk. Breast-feeding is not advised in mothers being treated. Not classified. |
| Reproductive toxicity Specific target organ toxicity - single exposure Specific target organ toxicity - repeated exposure | be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Pregnancy Category C: There are no adequate and well-controlled studies in pregnant women. This product passes into breast milk. Breast-feeding is not advised in mothers being treated. Not classified. |
| Reproductive toxicity Specific target organ toxicity - single exposure Specific target organ toxicity - repeated exposure Aspiration hazard | be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Pregnancy Category C: There are no adequate and well-controlled studies in pregnant women. This product passes into breast milk. Breast-feeding is not advised in mothers being treated. Not classified. Not classified. See package insert. |
| Reproductive toxicity Specific target organ toxicity - single exposure Specific target organ toxicity - repeated exposure Aspiration hazard Further information 12. Ecological information Ecotoxicity | be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Pregnancy Category C: There are no adequate and well-controlled studies in pregnant women. This product passes into breast milk. Breast-feeding is not advised in mothers being treated. Not classified. Not classified. See package insert. |
| Reproductive toxicity Specific target organ toxicity - single exposure Specific target organ toxicity - repeated exposure Aspiration hazard Further information 12. Ecological information | be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Pregnancy Category C: There are no adequate and well-controlled studies in pregnant women. This product passes into breast milk. Breast-feeding is not advised in mothers being treated. Not classified. Not classified. See package insert. The product is not classified as environmentally hazardous. No data is available on the degradability of this product. |
| Reproductive toxicity Specific target organ toxicity - single exposure Specific target organ toxicity - repeated exposure Aspiration hazard Further information 12. Ecological information Ecotoxicity | be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Pregnancy Category C: There are no adequate and well-controlled studies in pregnant women. This product passes into breast milk. Breast-feeding is not advised in mothers being treated. Not classified. Not classified. See package insert. The product is not classified as environmentally hazardous. |
| Reproductive toxicity Specific target organ toxicity - single exposure Specific target organ toxicity - repeated exposure Aspiration hazard Further information 12. Ecological information Ecotoxicity Persistence and degradability | be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Pregnancy Category C: There are no adequate and well-controlled studies in pregnant women. This product passes into breast milk. Breast-feeding is not advised in mothers being treated. Not classified. Not classified. See package insert. The product is not classified as environmentally hazardous. No data is available on the degradability of this product. No data available. ol / water (log Kow) |
| Reproductive toxicity Specific target organ toxicity - single exposure Specific target organ toxicity - repeated exposure Aspiration hazard Further information 12. Ecological information Ecotoxicity Persistence and degradability Bioaccumulative potential Partition coefficient n-octan 4-chloro-N-furfuryl-5-sulfamoy | be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Pregnancy Category C: There are no adequate and well-controlled studies in pregnant women. This product passes into breast milk. Breast-feeding is not advised in mothers being treated. Not classified. Not classified. See package insert. The product is not classified as environmentally hazardous. No data is available on the degradability of this product. No data available. ol / water (log Kow) |
| Reproductive toxicity Specific target organ toxicity - single exposure Specific target organ toxicity - repeated exposure Aspiration hazard Further information 12. Ecological information Ecotoxicity Persistence and degradability Bioaccumulative potential Partition coefficient n-octan 4-chloro-N-furfuryI-5-sulfamoy 54-31-9) | be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Pregnancy Category C: There are no adequate and well-controlled studies in pregnant women. This product passes into breast milk. Breast-feeding is not advised in mothers being treated. Not classified. Not classified. See package insert. The product is not classified as environmentally hazardous. No data is available on the degradability of this product. No data available. ol / water (log Kow) lanthranilic acid (CAS 2.03 |

13. Disposal considerations

| Disposal instructions | Collect and reclaim or dispose in sealed containers at licensed waste disposal site. |
|----------------------------|--|
| Local disposal regulations | Dispose in accordance with all applicable regulations. |

| Hazardous waste code | The waste code should be assigned in discussion between the user, the producer and the waste disposal company. | |
|--|--|--|
| Waste from residues / unused products | Dispose of in accordance with local regulations. Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe manner (see: Disposal instructions). | |
| Contaminated packaging | Empty containers should be taken to an approved waste handling site for recycling or disposal. Since emptied containers may retain product residue, follow label warnings even after container is emptied. | |
| 14. Transport information | | |
| DOT | | |
| Not regulated as dangerous g | oods. | |
| ΙΑΤΑ | | |
| Not regulated as dangerous g | 000S. | |
| Not regulated as dangerous g | oods. | |
| Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code | Not applicable. | |
| 15. Regulatory information | n | |
| US federal regulations | This material is not listed on the US TSCA Inventory. Therefore, it can only be used for TSCA exempt purposes such as R&D or drug use. | |
| TSCA Section 12(b) Export | Notification (40 CFR 707, Subpt. D) | |
| Not regulated. OSHA Specifically Regulate Not listed. | d Substances (29 CFR 1910.1001-1050) | |
| CERCLA Hazardous Substa Not listed. | nce List (40 CFR 302.4) | |
| | authorization Act of 1986 (SARA) | |
| Hazard categories | Immediate Hazard - No Delayed Hazard - No Fire Hazard - No Pressure Hazard - No Reactivity Hazard - No | |
| SARA 302 Extremely hazard | dous substance | |
| Not listed. | | |
| SARA 311/312 Hazardous chemical | No | |
| SARA 313 (TRI reporting) Not regulated. | | |
| Other federal regulations | Drug Enforcement Administration (DEA): Furosemide is not a controlled substance. | |
| | ction 112 Hazardous Air Pollutants (HAPs) List | |
| Not regulated. Clean Air Act (CAA) See Not regulated. | ction 112(r) Accidental Release Prevention (40 CFR 68.130) | |
| Safe Drinking Water Act (SDWA) | Not regulated. | |
| Not listed. | | |
| US state regulations | | |
| US. Massachusetts RTK - S | ubstance List | |
| - | Community Right-to-Know Act | |
| Not listed. US. Pennsylvania Worker an Not listed. | nd Community Right-to-Know Law | |
| | | |
| | | |

US. Rhode Island RTK

Not regulated.

US. California Proposition 65

California Safe Drinking Water and Toxic Enforcement Act of 1986 (Proposition 65): This material is not known to contain any chemicals currently listed as carcinogens or reproductive toxins.

International Inventories

| Country(s) or region | Inventory name | On inventory (yes/no)* |
|-----------------------------|---|------------------------|
| Australia | Australian Inventory of Chemical Substances (AICS) | Yes |
| Canada | Domestic Substances List (DSL) | Yes |
| Canada | Non-Domestic Substances List (NDSL) | No |
| China | Inventory of Existing Chemical Substances in China (IECSC) | No |
| Europe | European Inventory of Existing Commercial Chemical Substances (EINECS) | Yes |
| Europe | European List of Notified Chemical Substances (ELINCS) | No |
| Japan | Inventory of Existing and New Chemical Substances (ENCS) | Yes |
| Korea | Existing Chemicals List (ECL) | Yes |
| New Zealand | New Zealand Inventory | Yes |
| Philippines | Philippine Inventory of Chemicals and Chemical Substances (PICCS) | Yes |
| United States & Puerto Rico | Toxic Substances Control Act (TSCA) Inventory | No |

*A "Yes" indicates this product complies with the inventory requirements administered by the governing country(s).

A "No" indicates that one or more components of the product are not listed or exempt from listing on the inventory administered by the governing country(s).

16. Other information, including date of preparation or last revision

| Issue date | 30-December-2014 |
|---------------|--|
| Revision date | - |
| Version # | 01 |
| References | 1) Furosemide Oral Solution USP, Package Insert, West-Ward Pharmaceuticals Corporation, Columbus, |
| | Ohio |
| | 2) PDR – Physicians Desk Reference. |
| | 3) Ariel Webinsight. Regulatory and ChemExpert Database. |
| Disclaimer | West-Ward Pharmaceuticals Corporation cannot anticipate all conditions under which this information and its product, or the products of other manufacturers in combination with its product, may be used. It is the user's responsibility to ensure safe conditions for handling, storage and disposal of the product, and to assume liability for loss, injury, damage or expense due to improper use. The information in the sheet was written based on the best knowledge and experience currently available. |